Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786142 | 0.86 | HTT (0.45) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL1303921 | 0.84 | ALDH1A1 (0.50) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL18605987 | 0.84 | HTT (0.43) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL1302929 | 0.81 | ALDH1A1 (0.41) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL18839717 | 0.77 | MALT1 (0.40) | ALDH1A1GFERTDP1GAAMEN1 | |
| SCHEMBL1785691 | 0.75 | ALDH1A1 (0.50) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL15706334 | 0.75 | ALDH1A1 (0.43) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL18632908 | 0.75 | PKM (0.57) | ALDH1A1GFERHTTTDP1MEN1 | |
| SCHEMBL14602887 | 0.74 | ALDH1A1 (0.42) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL1302705 | 0.72 | JAK2 (0.42) | ALDH1A1GFERHTTTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998990-B2 | 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-2029562-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | ALDH1A1 4033/4885GFER 2684/4885HTT 1736/4885 |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | ALDH1A1 2527/4885GFER 3938/4885HTT 3970/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | ALDH1A1 2453/4885GFER 3890/4885HTT 3904/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | ALDH1A1 4022/4885GFER 3339/4885HTT 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.